Shah PD, Wethington SL, Pagan C, Latif N, et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecol Oncol 2021 Oct 4. pii: S0090-8258(21)01322.
PMID: 34620496